 CARSON CITY, Nev., Oct. 24, 2022 GLOBE NEWSWIRE -- BioVie Inc., NASDAQ: BIVI BioVie or the Company a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract characterizing the hospitalization burden of patients with cirrhosis and ascites and receiving treatment via paracentesis has been selected for presentation at The Liver Meeting 2022, the annual meeting of the American Association for the Study of Liver Diseases AASLD. The Liver Meeting 2022 will be held Washington, DC, from November 4-6, 2022. 